Amyotrophic Lateral Sclerosis Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Space

Amyotrophic Lateral Sclerosis Market
DelveInsight’s “Amyotrophic Lateral Sclerosis- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the ALS, historical and forecasted epidemiology as well as the ALS market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Amyotrophic Lateral Sclerosis – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Amyotrophic Lateral Sclerosis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Amyotrophic Lateral Sclerosis, historical and forecasted epidemiology as well as the Amyotrophic Lateral Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Amyotrophic Lateral Sclerosis Market Report:

The prevalent population of ALS in the seven major markets was 71,628 in 2020 and is expected to grow at a CAGR of 0.6% during the study period (2018-2030).
The diagnosed prevalent cases of ALS, in the United States, were 18,824 in 2020.
ALS can be divided into C9ORF72, SOD1, other mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutations based on the types of mutations causing the condition. In the United States, the number of cases of C9ORF72, SOD1, other mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation was 6,118, 3,012, 1,506, and 8,188, respectively, in 2020. 
In 2020, the patients with the limb site of onset accounted for 2,502 cases, followed by 1,251 cases with the bulbar site of onset, 801 cases with a cervical site of onset, and 450 cases with other uncertain regions in Germany.

Key benefits of the report:

Amyotrophic Lateral Sclerosis market report covers a descriptive overview and comprehensive insight of the Amyotrophic Lateral Sclerosis Epidemiology and Amyotrophic Lateral Sclerosis  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Amyotrophic Lateral Sclerosis market report provides insights on the current and emerging therapies.
Amyotrophic Lateral Sclerosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Amyotrophic Lateral Sclerosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Amyotrophic Lateral Sclerosis market.

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. 

Amyotrophic Lateral Sclerosis Market 

The dynamics of the Amyotrophic Lateral Sclerosis market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @ Amyotrophic Lateral Sclerosis Market Landscape 

Amyotrophic Lateral Sclerosis Pipeline Therapies and Key Companies 

Levosimendan:  Orion Pharma
NurOwn: Brainstorm-Cell Therapeutics
Arimoclomol: Orphazyme
Ibudilast: MediciNova
Tofersen: Biogen
Verdiperstat: Biohaven Pharmaceutical
Pridopidine: Prilenia Therapeutics
AMX0035: Amylyx
Pegcetacoplan: Apellis Pharmaceuticals

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Amyotrophic Lateral Sclerosis Patient Share (%) Overview at a Glance

5. Amyotrophic Lateral Sclerosis Market Overview at a Glance

6. Amyotrophic Lateral Sclerosis Disease Background and Overview

7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Amyotrophic Lateral Sclerosis 

9. Amyotrophic Lateral Sclerosis Current Treatment and Medical Practices

10. Unmet Needs

11. Amyotrophic Lateral Sclerosis Emerging Therapies

12. Amyotrophic Lateral Sclerosis Market Outlook

13. Country-Wise Amyotrophic Lateral Sclerosis Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Amyotrophic Lateral Sclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Amyotrophic Lateral Sclerosis Market Outlook 2030

Related Reports:

Amyotrophic Lateral Sclerosis Pipeline 

Amyotrophic Lateral Sclerosis Epidemiology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/